Feline leukemia vaccine: efficacy, contents and probable mechanism |
| |
| Authors: | J M Mastro M G Lewis L E Mathes R Sharpee M J Tarr R G Olsen |
| |
| Affiliation: | 1. Department of Biochemistry and Molecular Genetics, United States;2. James Graham Brown Cancer Center, United States;3. Division of Medical Oncology/Hematology, Department of Medicine, United States;4. Department of Radiation Oncology, United States;5. Division of Otolaryngology, Department of Surgery, University of Louisville School of Medicine, 529 S. Jackson St., Louisville, KY, United States;6. Data Science for Knowledge Creation Research Center, Department of Statistics, Seoul National University, Seoul, South Korea;1. Institute of Medical Microbiology, University Hospital Essen, University of Duisburg- Essen, Essen, Germany;2. Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;3. Inorganic Chemistry and Center for Nanointegration Duisburg-Essen (CeNIDE), University of Duisburg-Essen, Essen, Germany |
| |
| Abstract: | An effective subunit vaccine against feline leukemia virus infection and related diseases has been developed. The source of the vaccine immunogen is feline retrovirus persistently infected cells that continuously synthesize and shed virus polypeptides. Western blot analysis identifies FeLV-gp70, p27, p15, p12, and p10 in the subunit vaccine preparation. Cats immunized with the vaccine developed antibodies to a 70,000 MW protein of the vaccine that seems to be distinct from, but related to the FeLV-gp70 polypeptide. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
